A coffee variety called liberica, which is gaining popularity for the distinctive flavour of its beans, is actually three ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.9, a high estimate of $219.00, and a low estimate of $115.00. This current ...

Piper Sandler raised the firm’s price target on Biogen (BIIB) to $118 from $115 and keeps a Neutral rating on the shares. The ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending ...

Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting ...

The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...

Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

Biogen’s second quarter delivered results that exceeded Wall Street’s revenue and profit expectations, a performance that was ...

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.